Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifekalant injection versus amiodarone for life-threatening ventricular tachycardia or ventricular fibrillation
CTR20191725Phase 4Suspended
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nifekalant in ventricular tachycardia (VT), ventricular fibrillation (VF), sponsored by Biokin Pharmaceutical. Started Feb 2019; status: suspended.
02
Drugs
nifekalant
03
Conditions
ventricular tachycardia (VT)ventricular fibrillation (VF)
Beyond the preview
Go deeper on CTR20191725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191725.